Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus - PubMed (original) (raw)
Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus
C Bogedain et al. J Virol. 1995 Aug.
Abstract
We identified the immediate-early transactivator Zta of Epstein-Barr virus as a target for specific cytotoxic T lymphocytes (CTL). Cells pulsed with overlapping synthetic peptides representing the entire amino acid sequence of Zta proved to be efficient for the in vitro stimulation of Zta-specific CTL in several donors. With peptide-pulsed target cells, we found that CTL from several donors recognize a peptide comprising 15 amino acids. The immune response against this peptide exerted by CTL lines from different donors was found to be restricted by two different molecules of the major histocompatibility complex: HLA-B8 and HLA-Cw6. The latter molecule could for the first time be identified as a restricting element for a CTL response. The epitope of the HLA-B8-restricted CTL could be mapped to an octameric sequence between amino acid positions 190 and 197 of the Zta protein, whereas the minimal epitope of HLA-Cw6-restricted CTL consists of 11 to 15 residues between positions 187 and 201. Thus, the HLA-B8 and HLA-Cw6 epitopes widely overlap but are not completely identical. In vitro stimulation of blood lymphocytes from a panel of HLA-B8-positive or HLA-Cw6-positive virus carriers, using autologous cells pulsed with the Zta peptides comprising the HLA-B8 or HLA-Cw6 epitope, respectively, revealed in both cases that most of these donors developed a Zta-specific cytotoxic activity. These data, as well as the high spread of the major histocompatibility complex molecules HLA-B8 and HLA-Cw6 in most populations, suggest that an efficient CTL response directed against gene products of the immediate-early group of the lytic cycle exists in vivo in a considerable portion of virus carriers. A CTL response against proteins expressed immediately after the switch into the lytic cycle could eliminate lytically activated cells at an early stage and would thus efficiently prevent the production and release of progeny virions.
Similar articles
- Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.
Pepperl S, Benninger-Döring G, Modrow S, Wolf H, Jilg W. Pepperl S, et al. J Virol. 1998 Nov;72(11):8644-9. doi: 10.1128/JVI.72.11.8644-8649.1998. J Virol. 1998. PMID: 9765404 Free PMC article. - Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection.
Silins SL, Cross SM, Elliott SL, Pye SJ, Burrows JM, Moss DJ, Misko IS. Silins SL, et al. Int Immunol. 1997 Nov;9(11):1745-55. doi: 10.1093/intimm/9.11.1745. Int Immunol. 1997. PMID: 9418135 - Dominant cytotoxic T lymphocyte response to the immediate-early trans-activator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection.
Elliott SL, Pye SJ, Schmidt C, Cross SM, Silins SL, Misko IS. Elliott SL, et al. J Infect Dis. 1997 Oct;176(4):1068-72. doi: 10.1086/516513. J Infect Dis. 1997. PMID: 9333169 - Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response.
Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. Steven NM, et al. J Exp Med. 1997 May 5;185(9):1605-17. doi: 10.1084/jem.185.9.1605. J Exp Med. 1997. PMID: 9151898 Free PMC article. - Survey of Epstein Barr virus (EBV) immunogenic proteins and their epitopes: implications for vaccine preparation.
Rajcani J, Szenthe K, Banati F, Szathmary S. Rajcani J, et al. Recent Pat Antiinfect Drug Discov. 2014;9(1):62-76. doi: 10.2174/1574891x09666140828114812. Recent Pat Antiinfect Drug Discov. 2014. PMID: 25164057 Review.
Cited by
- Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD. Croft NP, et al. PLoS Pathog. 2009 Jun;5(6):e1000490. doi: 10.1371/journal.ppat.1000490. Epub 2009 Jun 26. PLoS Pathog. 2009. PMID: 19557156 Free PMC article. - Urea-mediated cross-presentation of soluble Epstein-Barr virus BZLF1 protein.
Barabas S, Gary R, Bauer T, Lindner J, Lindner P, Weinberger B, Jilg W, Wolf H, Deml L. Barabas S, et al. PLoS Pathog. 2008 Nov;4(11):e1000198. doi: 10.1371/journal.ppat.1000198. Epub 2008 Nov 7. PLoS Pathog. 2008. PMID: 18989461 Free PMC article. - Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus.
Kerr BM, Kienzle N, Burrows JM, Cross S, Silins SL, Buck M, Benson EM, Coupar B, Moss DJ, Sculley TB. Kerr BM, et al. J Virol. 1996 Dec;70(12):8858-64. doi: 10.1128/JVI.70.12.8858-8864.1996. J Virol. 1996. PMID: 8971014 Free PMC article. - Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL.
Lammoglia Cobo MF, Ritter J, Gary R, Seitz V, Mautner J, Aigner M, Völkl S, Schaffer S, Moi S, Seegebarth A, Bruns H, Rösler W, Amann K, Büttner-Herold M, Hennig S, Mackensen A, Hummel M, Moosmann A, Gerbitz A. Lammoglia Cobo MF, et al. PLoS Pathog. 2022 Apr 22;18(4):e1010206. doi: 10.1371/journal.ppat.1010206. eCollection 2022 Apr. PLoS Pathog. 2022. PMID: 35452490 Free PMC article. - Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC, Mowat AG, Fazou C, Rostron T, Roskell H, Dunbar PR, Tournay C, Romagné F, Peyrat MA, Houssaint E, Bonneville M, Rickinson AB, McMichael AJ, Callan MF. Tan LC, et al. Arthritis Res. 2000;2(2):154-64. doi: 10.1186/ar80. Epub 2000 Feb 7. Arthritis Res. 2000. PMID: 11062606 Free PMC article.
References
- Cell. 1978 May;14(1):9-20 - PubMed
- J Exp Med. 1993 Mar 1;177(3):751-62 - PubMed
- Proc Natl Acad Sci U S A. 1987 Mar;84(5):1332-6 - PubMed
- Int J Cancer. 1987 Apr 15;39(4):472-6 - PubMed
- J Virol. 1987 Jun;61(6):2054-8 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials